The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia

Fie Juhl VojdemanDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark; Correspondence[email protected]

Mars B. van't VeerDepartment of Hematology, Leiden University Medical Centre, Leiden, The Netherlands;

Geir E. TjønnfjordDepartment of Hematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway;

Maija Itälä-RemesTurku Central University Hospital, Turku, Finland;

Eva KimbyDivision of Hematology, Department of Medicine at Huddinge, Karolinska Institute, Stockholm, Sweden;

Aaron PolliackDepartment of Hematology, Hadassah University Hospital, Hebrew University Medical School, Jerusalem, Israel;

Ka L. WuDepartment of Hematology, Stuivenberg Hospital, Antwerpen, Belgium;

Jeanette K. DoorduijnDepartment of Hematology, Erasmus MC Cancer Center, Rotterdam, The Netherlands;

Wendimagegn G. AlemayehuHOVON Data Centre, Erasmus MC, Rotterdam, The Netherlands;

Shulamiet WittebolDepartment of Internal Medicine, Gelderse Vallei, Amersfoot, The Netherlands;

Tomas KozakDepartment of Clinical Hematology, Third Faculty of Medicine, Charles University Hospital Kralovske Vinohrady, Prague, Czech Republic;

Jan WalewskiLymphoid Malignancies, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland;

Martine C. J. Abrahamse-TestrooteHOVON Data Centre, Erasmus MC, Rotterdam, The Netherlands;

Marinus H. J. van OersDepartment of Hematology, Academisch Medisch Centrum, Amsterdam, The Netherlands

Christian Hartmann GeislerDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark;

Articles from other publishers (8)